Alimera Sciences (ALIM) Rating Reiterated by HC Wainwright

Alimera Sciences (NASDAQ:ALIM)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued on Wednesday. They currently have a $3.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 172.73% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. Cowen reaffirmed a “buy” rating and set a $3.00 price target on shares of Alimera Sciences in a report on Wednesday, September 5th. Zacks Investment Research raised Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a report on Thursday, August 2nd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $2.44.

Shares of Alimera Sciences stock opened at $1.10 on Wednesday. Alimera Sciences has a 1 year low of $0.74 and a 1 year high of $1.38.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The business had revenue of $11.14 million for the quarter, compared to analyst estimates of $11.12 million. Research analysts anticipate that Alimera Sciences will post -0.27 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Stonepine Capital Management LLC lifted its holdings in shares of Alimera Sciences by 13.0% during the second quarter. Stonepine Capital Management LLC now owns 6,981,184 shares of the biopharmaceutical company’s stock worth $6,830,000 after buying an additional 801,151 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Alimera Sciences by 20.8% during the second quarter. Renaissance Technologies LLC now owns 574,000 shares of the biopharmaceutical company’s stock worth $562,000 after buying an additional 99,000 shares in the last quarter. Finally, BlackRock Inc. lifted its holdings in shares of Alimera Sciences by 28.5% during the second quarter. BlackRock Inc. now owns 272,248 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 60,327 shares in the last quarter. 51.84% of the stock is owned by institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Featured Story: Stock Split

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply